Effect of Immune X on Common Cold Incidence in Healthy Adults (CELFI)
The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:
- Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?
- Does Immune X affect the number, duration, and severity of common cold events?
Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.
Participants will:
- Take Immune X or placebo daily for 16 weeks during the winter season.
- Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.
- Record cold symptoms, medications, and other study information using a smartphone application.
- Provide blood and stool samples during the study.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Katja A. Schönenberger, PhD
- Numer telefonu: +41 52 354 01 11
- E-mail: katja.schoenenberger@givaudan.com
Kopia zapasowa kontaktu do badania
- Nazwa: Linda Lopez, PhD
- Numer telefonu: +41 52 354 01 11
- E-mail: linda.lopez@givaudan.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Men and women aged 18 to 65 years.
- History of at least two upper respiratory tract infections during the previous winter season.
- Body mass index between 18 and 30 kg/m².
- Generally healthy, as determined by the investigator.
- Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.
- Covered by French health insurance.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.
- Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.
- Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.
- Use of systemic antibiotics within 3 months before enrollment.
- Receipt of any vaccination within 6 weeks before enrollment.
- Surgery requiring general anesthesia within 1 month before enrollment.
- History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.
- Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.
- Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.
- Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.
- Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.
- Untreated or inadequately controlled diabetes.
- History or current diagnosis of periodontitis.
- Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.
- Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.
- Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.
- Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.
- Current drug or alcohol abuse, or a history of abuse within the previous 12 months.
- Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.
- Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.
- More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.
- Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.
- Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.
- Pregnant or breastfeeding.
- Persons deprived of liberty, under legal protection, or unable to provide informed consent.
- Individuals who have reached the regulatory compensation limit for participation in clinical research.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Immune X
80 participants who meet the eligibility criteria will be randomized to the experimental arm and will receive Immune X for 16 weeks.
|
500 mg Immune X daily as capsules for 16 weeks.
|
|
Komparator placebo: Placebo
80 participants who meet the eligibility criteria will be randomized to the placebo arm and will receive placebo for 16 weeks.
|
Matching placebo capsules daily for 16 weeks.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Participants With at Least One Clinically Confirmed Cold Event
Ramy czasowe: Week 2 to Week 16
|
Proportion of participants with at least one clinically confirmed cold event.
|
Week 2 to Week 16
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Clinically Confirmed Cold Events
Ramy czasowe: Week 2 to Week 16
|
Mean number of clinically confirmed cold events per participant.
|
Week 2 to Week 16
|
|
Duration of Clinically Confirmed Cold Events
Ramy czasowe: Week 2 to Week 16
|
Duration of clinically confirmed cold events measured in days.
|
Week 2 to Week 16
|
|
Upper Respiratory Symptoms of Clinically Confirmed Cold Events
Ramy czasowe: Week 2 to Week 16
|
Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.
|
Week 2 to Week 16
|
|
Cold Symptoms of Clinically Confirmed Cold Events
Ramy czasowe: Week 2 to Week 16
|
Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms
|
Week 2 to Week 16
|
|
Illness-Specific Quality of Life During Cold Events
Ramy czasowe: Week 2 to Week 16
|
Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.
|
Week 2 to Week 16
|
|
Time to First Clinically Confirmed Cold Event
Ramy czasowe: Week 2 to Week 16
|
Number of days from Day 15 after randomization to the first clinically confirmed cold event.
|
Week 2 to Week 16
|
|
Fatigue
Ramy czasowe: Baseline, Weeks 4, 8, 12, and 16
|
Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.
|
Baseline, Weeks 4, 8, 12, and 16
|
|
Use of Rescue Medication During Cold Events
Ramy czasowe: Week 2 to Week 16
|
Number of doses and duration of rescue medication use during cold events.
|
Week 2 to Week 16
|
|
Number of Cold Events (Clinically Confirmed and Unconfirmed)
Ramy czasowe: Week 2 to Week 16
|
Mean number of clinically confirmed and unconfirmed cold events per participant.
|
Week 2 to Week 16
|
|
Adverse Events
Ramy czasowe: Baseline through Week 16
|
Number of participants with adverse events.
|
Baseline through Week 16
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Carole Perrin, MD, Cen Experimental
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- C1775
- 2026-A00903-48 (Inny identyfikator: ID-RCB)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .